Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3870564 | 0.84 | PGR (1.00) | PGR | |
| SCHEMBL3881351 | 0.84 | PGR (1.00) | PGR | |
| SCHEMBL3874143 | 0.81 | PGR (1.00) | PGR | |
| SCHEMBL3870133 | 0.81 | PGR (1.00) | PGR | |
| SCHEMBL3872470 | 0.81 | PGR (1.00) | PGR | |
| SCHEMBL3882998 | 0.81 | PGR (1.00) | PGR | |
| SCHEMBL4104445 | 0.80 | PGR (0.71) | PGR | |
| SCHEMBL7605568 | 0.78 | PGR (0.87) | PGR | |
| SCHEMBL3870851 | 0.78 | PGR (1.00) | PGR | |
| SCHEMBL3870650 | 0.77 | PGR (1.00) | PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329690-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators | WYETH LLC (US) | 2012-12-11 | — | — | US | claimed |
| US-20090281096-A1 | CYCLOTHIOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2009-11-12 | — | — | US | claimed |
| EP-1175411-B1 | CYCLOTHIOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | WYETH CORP (US) | 2008-02-20 | — | — | EP | claimed |
| US-20060142280-A1 | Such as 4-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1 ,3]oxazin-6-yl)-thiophene-2-carbonitrile; estrogen receptor agonists, progesterone receptor antagonists; hormone replacement therapy | WYETH (US) | 2006-06-29 | — | — | US | claimed |
| EP-1515725-A4 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH CORP (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1515725-A2 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | Wyeth (US) | 2005-03-23 | — | — | EP | claimed |
| US-20040014798-A1 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | WYETH | 2004-01-22 | — | — | US | claimed |
| US-20040006060-A1 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | WYETH | 2004-01-08 | — | — | US | claimed |
| WO-2004000801-A2 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH (US) | 2003-12-31 | — | — | WO | claimed |
| US-20030092711-A1 | Contraceptives; hormone replacement therapy | WYETH LLC | 2003-05-15 | — | — | US | claimed |
| US-6436929-B1 | 3,1-BENZOXAZINE-2-THIONES; CONTRACEPTION AND THE TREATMENT OF PROGESTERONE-RELATED MALADIES | WYETH | 2002-08-20 | — | — | US | claimed |
| US-8796266-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators | WYETH LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130261112-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | WYETH LLC | 2013-10-03 | — | — | US | disclosed |
| US-8466146-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators | WYETH LLC (US) | 2013-06-18 | — | — | US | disclosed |
| US-20130072480-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | WYETH LLC (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2004000230-A2 | CYCLOTHIOCARBAMATIVE DERIVATIVES AS PR MODULATORS AND USE THEREOF FOR TREATMENT OF SKIN DISORDERS | WYETH (US) | 2003-12-31 | — | — | WO | disclosed |
| US-20030092711-A1 | Contraceptives; hormone replacement therapy | WYETH LLC | 2003-05-15 | — | — | US | disclosed |
| US-6436929-B1 | 3,1-BENZOXAZINE-2-THIONES; CONTRACEPTION AND THE TREATMENT OF PROGESTERONE-RELATED MALADIES | WYETH | 2002-08-20 | — | — | US | disclosed |
| EP-1175411-A1 | CYCLOTHIOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | American Home Products Corporation (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066570-A1 | CYCLOTHIOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142280-A1 | Such as 4-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1 ,3]oxazin-6-yl)-thiophene-2-carbonitrile; estrogen receptor agonists, progesterone receptor antagonists; hormone replacement therapy | PGR, ESR1, GPER1 | PGR 1/4885 |
| US-20090281096-A1 | CYCLOTHIOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | PGR, PGRMC2, PGRMC1 | PGR 1/4885 |
| US-20030092711-A1 | Contraceptives; hormone replacement therapy | PGR, GNRHR, GHRHR | PGR 1/4885 |
| US-20040006060-A1 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | ESRRA, GNRHR, ESRRG | PGR 46/4885 |
| US-20130072480-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | PGR, PGRMC2, PGRMC1 | PGR 1/4885 |
| US-20130261112-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | PGR, PGRMC2, PGRMC1 | PGR 1/4885 |
| US-20040014798-A1 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | NR5A1, MC1R, CYP17A1 | PGR 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.